Drug
Izalontamab clinical trials
Also written SI-B001.
How studies write it
Studies that test it under each name
Development codes
- SI-B001
- 8
Studies by the year they started
8 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Docetaxel (2) · Danvilostomig (2) · Paclitaxel (1) · Osimertinib (1) · Irinotecan (1)
Studies
Open first, then newest update. How each study uses izalontamab is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCActive, not recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05054439Written as SI-B001
- A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT05668858Written as SI-B001
- A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT05949606Written as SI-B001
- SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.Active, not recruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT05020769Written as SI-B001
- A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCCActive, not recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05044897Written as SI-B001
- SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.Active, not recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05022654Written as SI-B001
- A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial TumorsActive, not recruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT04603287Written as SI-B001
- A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaActive, not recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT05943795Written as SI-B001
Given in every arm · 3 — izalontamab is usual care beside what is tested
- A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06668961Written as SI-B001
- SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.Active, not recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05020457Written as SI-B001
- SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System MalignanciesTerminatedPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05039944Written as SI-B001
Codes
What other systems call izalontamab · ClinicalTrials.gg INT017877
- UNII (FDA) S8YH2C9NLAIZALONTAMABOne source FDA
- NCI Thesaurus C178396IzalontamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S8YH2C9NLA | IZALONTAMAB | One source FDA |
| NCI Thesaurus | C178396 | Izalontamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.